Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.0	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.0	0.796	0.01	-0.00637	1.0	0.92
BT-20	ZSTK474	2	72	sigmoid	sigmoid	BT20 ZSTK474 0 2 72	8	1.787	0.286	-0.19	0.347	0.373	-0.234	1.46	0.992	4.53e-07	NA	0.391	0.199	0.743	0.29	0.184	1.55	0.988	1.84e-06	NA
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.0	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.0	0.914	0.01	0.418	0.197	0.951
HCC1806	Everolimus	2	72	sigmoid	sigmoid	HCC1806 everolimus 0 2 72	8	2.871	Inf	0.79	0.178	0.000277	0.79	0.365	0.879	0.00176	NA	Inf	0.727	0.765	0.000222	0.728	0.374	0.879	0.00178	NA
BT-549	AZD-6482	2	72	sigmoid	sigmoid	BT549 AZD6482 0 2 72	8	1.973	9.15	0.635	0.112	120.0	-1.0	0.426	0.951	0.000115	NA	19.4	0.672	0.895	19.4	0.0	0.437	0.946	0.000154	NA
BT-549	AZD8055	2	72	sigmoid	sigmoid	BT549 AZD8055 0 2 72	8	1.848	0.0373	0.14	0.506	0.0287	0.138	1.23	0.994	2.1e-07	NA	0.0653	0.354	0.605	0.0239	0.35	1.2	0.995	1.39e-07	NA
BT-549	Dactolisib	2	72	sigmoid	sigmoid	BT549 dactolisib 0 2 72	8	1.889	0.00968	-0.00862	0.677	0.00884	0.0542	1.27	0.985	3.3e-06	NA	0.0134	0.266	0.48	0.00701	0.305	1.45	0.988	1.53e-06	NA
HCC1806	Pictilisib	2	72	sigmoid	sigmoid	HCC1806 pictilisib 0 2 72	8	2.866	12.1	0.796	0.0476	45.4	-1.0	0.831	0.811	0.00671	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
BT-549	Buparlisib	2	72	sigmoid	sigmoid	BT549 buparlisib 0 2 72	8	1.913	0.681	-0.306	0.217	1.08	-0.538	1.59	0.998	1.31e-08	NA	0.821	0.132	0.838	0.769	0.0514	1.66	0.996	8.95e-08	NA
BT-549	BX-912	2	72	sigmoid	sigmoid	BT549 BX-912 0 2 72	8	1.948	1.04	0.33	0.126	0.84	0.329	5.0	0.99	1.01e-06	NA	1.28	0.452	0.892	0.808	0.451	5.0	0.987	2.4e-06	NA
Hs 578T	Omipalisib	2		sigmoid	sigmoid	Hs578T omipalisib 2	8	2.507	0.0155	-0.52	0.766	0.239	-1.0	0.402	0.993	3.45e-07	NA	0.0114	0.028	0.355	0.0114	0.0	0.468	0.981	6.9e-06	NA
BT-549	Alpelisib	2	72	sigmoid	sigmoid	BT549 alpelisib 0 2 72	8	1.927	Inf	0.832	0.0409	4.24	0.663	0.548	0.706	0.0254	NA	Inf	0.844	0.962	4.26	0.686	0.542	0.696	0.0282	NA
HCC1806	GDC-0980	2	72	sigmoid	sigmoid	HCC1806 apitolisib 0 2 72	8	2.781	1.32	0.355	0.148	0.746	0.241	1.15	0.995	1.49e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
BT-549	CAL-101	2	72	sigmoid	sigmoid	BT549 idelalisib 0 2 72	8	1.975	Inf	0.792	0.0561	4.65	0.526	0.693	0.933	0.000307	NA	43.0	0.805	0.946	43.0	0.0	0.548	0.932	0.000314	NA
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
BT-549	Pictilisib	2	72	sigmoid	sigmoid	BT549 pictilisib 0 2 72	8	1.960	1.84	0.365	0.166	11.5	-1.0	0.599	0.943	0.000187	NA	2.82	0.473	0.851	2.82	0.0	0.647	0.924	0.000432	NA
HCC1806	Omipalisib	2	72	sigmoid	sigmoid	HCC1806 omipalisib 0 2 72	8	2.849	0.112	-0.311	0.479	0.543	-0.739	0.573	0.98	8.07e-06	NA	0.0642	0.0481	0.54	0.0538	0.0749	0.919	0.979	9.93e-06	NA
BT-549	GDC-0980	2	72	sigmoid	sigmoid	BT549 apitolisib 0 2 72	8	1.939	0.189	0.0264	0.357	0.193	-0.011	1.04	0.997	2.98e-08	NA	0.278	0.274	0.71	0.142	0.257	1.07	0.997	3.64e-08	NA
BT-549	Omipalisib	2	72	sigmoid	sigmoid	BT549 omipalisib 0 2 72	8	1.990	0.0104	-0.291	0.751	0.026	-0.32	0.542	0.966	4.09e-05	NA	0.0175	0.127	0.422	0.011	0.118	0.58	0.953	0.000102	NA
BT-549	KIN001-244	2	72	sigmoid	sigmoid	BT549 KIN001-244 0 2 72	8	1.920	Inf	0.882	0.00561	2.72	0.793	1.67	0.73	0.0197	NA	Inf	0.89	0.995	2.6	0.813	1.68	0.718	0.0225	NA
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.0	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
BT-549	PI103	2	72	sigmoid	sigmoid	BT549 PI-103 0 2 72	8	1.893	0.218	0.0201	0.344	0.229	-0.0262	1.08	0.997	2.55e-08	NA	0.326	0.28	0.725	0.169	0.261	1.13	0.996	6.2e-08	NA
Hs 578T	KIN001-244	2		sigmoid	sigmoid	Hs578T KIN001-244 2	8	2.505	Inf	0.819	0.0357	4.8	0.531	1.14	0.891	0.0013	NA	44.3	0.788	0.957	4.79	0.457	1.1	0.878	0.0018	NA

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)